Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma

The role of IL-21 in immunity and cancer

(2015) Matthew R. Davis et al.   CANCER LETTERS

Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy

(2015) Markus Granzin et al.   CYTOTHERAPY

Multiple effects of IL-21 on human NK cells in ex vivo expansion

(2015) Qi Li et al.   IMMUNOBIOLOGY

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

(2015) Susann Szmania et al.   JOURNAL OF IMMUNOTHERAPY

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens

(2015) Richard W. Childs et al.   NATURE REVIEWS DRUG DISCOVERY

Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies–A review

(2015) Sandeep Nayar et al.   OncoImmunology

Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy

(2014) Jeffrey S. Miller et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Infusions of Allogeneic Natural Killer Cells as Cancer Therapy

(2014) W. Leung   CLINICAL CANCER RESEARCH

Effect of exposure to interleukin-21 at various time points on human natural killer cell culture

(2014) Dong-Pyo Lim et al.   CYTOTHERAPY

Are natural killer cells superior CAR drivers?

(2014) Hans Klingemann   OncoImmunology

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

Cellular therapy of cancer with natural killer cells—where do we stand?

(2013) Hans G. Klingemann   CYTOTHERAPY

T-helper-1-cell cytokines drive cancer into senescence

(2013) Heidi Braumüller et al.   NATURE

Bringing natural killer cells to the clinic: ex vivo manipulation

(2013) R. W. Childs et al.   Hematology-American Society of Hematology Education Program

Toward the next generation of NK cell-based adoptive cancer immunotherapy

(2013) Jing Ni et al.   OncoImmunology

Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors

(2012) Jing Ni et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells

(2012) Cecele J. Denman et al.   PLoS One

New insights into the role of NK cells in cancer immunotherapy

(2012) Maria Salagianni et al.   OncoImmunology

Allogeneic natural killer cells for refractory lymphoma

(2010) Veronika Bachanova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

(2010) Melissa A. Geller et al.   CYTOTHERAPY

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-21 augments natural killer effector functions in chronically HIV-infected individuals

(2009) Natasa Strbo et al.   AIDS

Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

(2009) Maria Berg et al.   CYTOTHERAPY

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

(2008) S. Arai et al.   CYTOTHERAPY

IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

(2008) Bin Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION